Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2024-10-10 Regulatory Filings
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding a rectification order received from the Income Tax Department deleting a tax demand for a subsidiary. It is addressed to stock exchanges and includes details as required by SEBI regulations. The document is short (2939 characters) and serves as a regulatory update about a tax matter, not a full financial report or audit. It does not contain financial statements or detailed analysis but is a compliance disclosure. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-10 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the cancellation and dematerialization of physical share certificates for the quarter ended September 30, 2024. It is addressed to stock exchanges and the company secretary, and it is a compliance certificate rather than a financial report or announcement of financial results. The document length is short (2996 characters) and it primarily serves as a regulatory compliance certificate. This fits the definition of a Regulatory Filing (RNS) as it is a regulatory announcement and certification rather than a financial report or other specific filing type.
2024-10-09 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure letter addressed to stock exchanges (BSE and NSE) regarding a corporate transaction. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events by listed companies in India. The content details the exercise of a put option leading to acquisition of 80% equity in a newly incorporated company, Jasmin, by a subsidiary of the listed company. It includes specifics about the acquisition, regulatory approvals, consideration, and timeline. There are no financial statements or detailed financial performance data, nor is this a report or presentation. This is a regulatory announcement about a material corporate event (acquisition). Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a significant capital transaction and acquisition update.
2024-10-04 English
Appointment
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges referencing SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It announces two key items approved by the Board of Directors: (1) the grant of stock options/RSUs to employees under an employee stock option plan, and (2) the appointment of a senior management personnel, Dr. Tushar Gupta, as Chief of Operations. The document includes detailed information about the stock option grant and the appointment, including an annexure with the appointee's profile. There are no financial statements or comprehensive financial data presented, nor is this a report or earnings release. The content primarily concerns a management appointment and stock option grant disclosures, which are regulatory announcements related to management and capital incentives. Given the appointment of a senior management person and the stock option grant, the classification that best fits is "Board/Management Information (MANG)" as it includes announcements of changes in senior management and related disclosures. The document length and detail support this classification rather than a brief announcement or a regulatory filing fallback. Confidence is high due to clear references to management appointment and stock option grant under SEBI regulations.
2024-10-01 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges referencing SEBI Listing Regulations, specifically Regulation 33 and Regulation 30, which relate to disclosure obligations. It announces two key items approved by the Board of Directors: (1) the grant of stock options/RSUs to employees under an employee stock option plan, and (2) the appointment of a senior management personnel (Dr. Tushar Gupta) as Chief of Operations. The document includes detailed information about the stock option grant and the appointment, including an annexure with the appointee's profile. There are no financial statements or comprehensive financial data presented, nor is this a report of financial results or an audit. Instead, it is an announcement of a management appointment and a stock option grant, which is a capital/financing update. The appointment of a senior management person also aligns with Board/Management Information, but since the document also includes the stock option grant details, the primary classification is Capital/Financing Update (CAP). The document length (6295 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure under SEBI regulations. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-10-01 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice from Jubilant Pharmova Limited informing stock exchanges about the closure of the trading window for insiders ahead of the announcement of quarterly and half-year financial results. It does not contain any financial data, results, or detailed report content. It is an announcement related to compliance with insider trading regulations and timing of financial results disclosure. The document length is only 1600 characters, indicating it is a brief announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance notices that do not fit other categories.
2024-09-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.